Screener
Neuropace, Inc. NPCE Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:33 PM EDT
- Fiscal quarter
- Q4 FY2030
- Calendar quarter
- Q4 2030
- Accession
- 0001528287-26-000030
| (in thousands, except for share and per share amounts) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 5) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value, 200,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 34,282,567 and 33,574,759 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 34 | 34 |
| Additional paid-in capital | 577,153 | 571,412 |
| Accumulated deficit | (565,304) | (552,415) |
| Total stockholders’ equity | 11,883 | 19,031 |
| Total liabilities and stockholders’ equity | $96,991 | $105,565 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Neuropace, Inc.'s common stock?
- Neuropace, Inc. (NPCE) reported common stock of 200M in Q2 2026.
- How has Neuropace, Inc.'s common stock changed year-over-year?
- Neuropace, Inc.'s common stock decreased by 0.0% year-over-year, from 200M to 200M.
- What is the long-term trend for Neuropace, Inc.'s common stock?
- Over 5 years (2020 to 2025), Neuropace, Inc.'s common stock has grown at a 21.8% compound annual growth rate (CAGR), from 74.6M to 200M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Neuropace, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude